Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New pharmacologic agents for diabetes.

C J Bailey1

  • 1Department of Pharmaceutical Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.

Current Diabetes Reports
|March 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.

Clinical pharmacology and therapeutics·2015
Same author

Safety of antidiabetes medications: An update.

Clinical pharmacology and therapeutics·2015
Same author

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.

Diabetes, obesity & metabolism·2014
Same author

A cotyledon slice system for the electron autoradiographic study of the synthesis and intracellular transport of the seed storage protein of Vicia faba.

Planta·2014
Same author

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Diabetes, obesity & metabolism·2012

New pharmacologic approaches are emerging to treat type 2 diabetes. These novel agents target underlying metabolic disturbances, including insulin resistance and hyperglycemia, offering improved patient outcomes.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Diabetes Research

Background:

  • Type 2 diabetes involves complex endocrinopathies and metabolic disturbances.
  • Existing treatments aim to manage hyperglycemia and dyslipidemia.
  • There is a continuous need for novel therapeutic strategies.

Purpose of the Study:

  • To review emerging pharmacologic approaches for type 2 diabetes.
  • To highlight novel drug targets and mechanisms of action.
  • To discuss agents addressing multiple pathophysiologic lesions.

Main Methods:

  • Review of current research on new diabetes medications.
  • Analysis of drug classes targeting nuclear receptors (PPARs).
  • Evaluation of agents affecting insulin signaling and incretin pathways.

Related Experiment Videos

Main Results:

  • Peroxisome proliferator-activated receptor (PPAR) agonists show promise for insulin sensitivity and lipid control.
  • Novel insulin receptor modulators offer new therapeutic avenues.
  • Glucagon-like peptide-1 analogues may enhance insulin secretion and beta-cell function.

Conclusions:

  • Emerging pharmacologic strategies target diverse mechanisms in type 2 diabetes.
  • PPAR agonists, insulin pathway modulators, and incretin analogues represent promising new treatments.
  • These advancements offer hope for more effective management of type 2 diabetes.